Hanmi Pharm signs $2.3 bil. licensing deal with Roche's Genentech for obesity drug candidate
Hanmi Pharm, a Korean pharmaceutical company, said Monday it has signed a 3.2 trillion-won ($2.3 billion) licensing deal with Genentech, a U.S.-based member of the Roche Group, for an obesity drug candidate designed to reduce body fat while preserving and increasing muscle mass. Hanmi Pharm has signed an exclusive licensing agreement with Genentech for the development, manufacturing and…
Hanmi Pharm, a Korean pharmaceutical company, has entered into a significant licensing agreement worth $2.3 billion with Genentech, a U.S.-based subsidiary of the Roche Group. The deal pertains to an innovative obesity drug candidate named HM17321, which is designed to reduce body fat while preserving and increasing muscle mass.
This long-acting uro-cortin-2 (UCN2) analog is expected to offer a differentiated approach to treating obesity and related conditions, including type 2 diabetes. In the agreement, Genentech secures exclusive rights to research, develop, manufacture, and commercialize HM17321 globally, with the exception of Korea where Hanmi retains the rights.
Written by urgent.news from The Korea Times's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
This story
This is one outlet's version. Read the fullest account.
- Hanmi Licenses Obesity Drug To Genentech businesskorea.co.kr
- Hanmi Pharm signs $2.3 bil. licensing deal with Roche's Genentech for obesity drug candidate koreatimes.co.kr
- Hanmi Pharm shares jump 30% on Genentech obesity drug deal investing.com
- Roche bets up to $2.3B on Hanmi’s early-stage muscle-building obesity asset endpoints.news
- Hanmi Pharm signs 3.2 tln-won licensing deal with Roche's Genentech for obesity drug candidate en.yna.co.kr
